Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, Y. Articles by Fukami, K. Search for Related Content PubMed PubMed Citation Articles by Nakamura, Y. Articles by Fukami, K.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, December 2005, p. 10979-10988, Vol. 25, No. 24
0270-7306/05/$08.00+0     doi:10.1128/MCB.25.24.10979-10988.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Phospholipase C-1 and -3 Are Essential in the Trophoblast for Placental Development

Yoshikazu Nakamura,¹ Yoshio Hamada,² Takashi Fujiwara,³ Hiroko Enomoto,¹ Takeshi Hiroe,⁴ Satoshi Tanaka,⁵ Masato Nose,⁶ Masamichi Nakahara,¹ Nobuaki Yoshida,⁷ Tadaomi Takenawa,⁸ and Kiyoko Fukami^1*

Laboratory of Genome and Biosignal, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, 192-0392 Tokyo, Japan,¹ Tissue and Cell Culture Laboratory, National Institute For Basic Biology, 38 Nishigonaka, Myodaiji, Okazaki, Aichi 444-8585, Japan,² Laboratory Animal Center, Ehime University School of Medicine, Shitsukawa, Shigenobu-cho, Onsen-gun, Ehime 791-0295, Japan,³ Center for Experimental Animals, National Institute for Physiological Sciences, 38 Nishigonaka, Myodaiji, Okazaki 444-8585, Japan,⁴ Laboratory of Cellular Biochemistry, Department of Animal Resource Sciences/Veterinary Medical Sciences, The University of Tokyo, Yayoi 1-1-1, Bukyo-ku, Tokyo 113-8657, Japan,⁵ Department of Pathology, Ehime University School of Medicine, Shitsukawa, Shigenobu-cho, Onsen-gun, Ehime 791-0295, Japan,⁶ Division of Gene Expression and Regulation, The Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan,⁷ Department of Biochemistry, The Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan⁸

Received 19 August 2005/ Returned for modification 2 September 2005/ Accepted 18 September 2005

Top Abstract Introduction Materials and Methods Results Discussion References

 
Phosphoinositide-specific phospholipase C (PLC) is a key enzyme in phosphoinositide turnover and is involved in a variety of physiological functions. We analyzed PLC1 knockout mice and found that PLC1 is required for the maintenance of skin homeostasis. However, there were no remarkable abnormalities except hair loss and runting in PLC1 knockout mice, even though PLC1 is broadly distributed. Here, we report that mice lacking both PLC1 and PLC3 died at embryonic day 11.5 (E11.5) to E13.5. PLC1/PLC3 double-knockout mice exhibited severe disruption of the normal labyrinth architecture in the placenta and decreased placental vascularization, as well as abnormal proliferation and apoptosis of trophoblasts in the labyrinth area. Furthermore, PLC1/PLC3 double-knockout embryos supplied with a normal placenta by the tetraploid aggregation method survived beyond E14.5, clearly indicating that the embryonic lethality is caused by a defect in trophoblasts. On the basis of these results, we conclude that PLC1 and PLC3 are essential in trophoblasts for placental development.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Phosphoinositide-specific phospholipase C (PLC) hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate two second messengers, diacylglycerol and inositol 1,4,5-trisphosphate. Diacylglycerol mediates the activation of protein kinase C, and inositol 1,4,5-trisphosphate releases calcium from intracellular stores (1, 19).

PLC can be categorized into six types, ß, , , , , and , on the basis of sequence homology and activation mechanism (5, 13, 20, 21, 23, 24, 34). Each isozyme is composed of subtype-specific and conserved domains. All PLC isozymes contain catalytic X and Y domains, as well as various regulatory domains, including the C2 domain, EF-hand motif, and pleckstrin homology domain. Subtype-specific domains contribute to the specific regulatory mechanisms. These domains include the src homology domain in PLC (23) and the Ras-associating domain and Ras-GTPase exchange factor-like domain in PLC (15, 29).

PLC types are evolutionarily conserved from lower to higher eukaryotes, and these isozymes are thought to be the primary forms expressed in mammals. Therefore, PLC is expected to have important and basic physiological functions. There are three PLC isozymes, PLC1, -3, and -4 (10). It has been suggested that PLC1 is involved in Alzheimer's disease (27) and essential hypertension (14, 35). Recently, we analyzed PLC knockout (KO) mice and found that PLC1 has an important role in skin homeostasis (18) and that PLC4 is involved in the acrosome reaction of sperm (6, 7). These results provide some clarification of the physiological functions of PLC1 and PLC4; however, the function of PLC3 remains unknown.

In the present study, to elucidate the physiological roles of PLC3, we analyzed PLC3 KO mice. Thus far, PLC3 KO mice have exhibited no obvious abnormalities. Because PLC3 is most similar to PLC1, we generated mice lacking both PLC1 and PLC3 genes (PLC1/PLC3 double-knockout [DKO] mice). We found that simultaneous disruption of PLC1 and PLC3 resulted in embryonic lethality at midgestation. In PLC1/PLC3 DKO mice, the structure of the placental labyrinth layer was abnormal, and placental vascularization was decreased. Furthermore, tetraploid (4N) aggregation experiments revealed that the primary cause of embryonic lethality is a trophoblast defect. Thus, PLC1 and PLC3 play important roles in normal development of the placenta.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Generation of PLC3 KO mice. PLC3 heterozygous (PLC3^+/–) mice were generated by Lexicon Genetics Incorporated (The Woodlands, TX) from Omni Bank clone OST101546 as described previously (37). Once germ line transmission had been validated by PCR, the PLC3^+/– animals were mated with an animal with a C57BL/6J background, resulting in a 129Sv/lex x C57BL/6J hybrid background.

Mouse breeding to generate PLC1/PLC3 DKO mice. PLC1 KO strains have been described previously (18). To generate PLC1/PLC3 DKO mice, the PLC1 and PLC3 KO mouse lines were interbred. Mouse tail tips, small parts of yolk sacs, or embryos were used for genotyping by PCR. Primers for PCR analysis of PLC1 were described previously (18). Primers for PLC3 were 5'-TTAACCTGATGCTCCTGAGG-3', 5'-GGATAAAATGCTTGCCCTGC-3', and 5'-AAAATGGCGTTACTTAAGCTTGC-3'. Gene targeting was also verified by Western blot analysis with appropriate antibodies.

Antibodies and Western blot analysis. Mouse monoclonal antibodies against PLC3 were developed by immunizing PLC3 KO mice with full-length mouse PLC3 protein as an antigen. PLC1 polyclonal antibody was a gift from Pann-Ghill Suh (POSTECH, Korea). Anti-ß-actin antibody was purchased from Chemicon (Temecula, CA). Various tissues or cells for Western blot analysis were homogenized with a buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100), sonicated, and centrifuged for 15 min at 13,000 x g to remove insoluble debris. Sodium dodecyl sulfate (SDS) sample buffer was then added, and the mixture was incubated for 5 min at 95°C. The lysates were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and probed with antibodies as described previously (17).

Histochemistry and immunohistochemistry. For histological analyses, placentas were fixed in 4% paraformaldehyde or 2% glutaraldehyde, dehydrated, and embedded in paraffin. Sections (5 µm) were stained with hematoxylin and eosin (HE). For PLC1 immunohistochemistry, placentas were fixed overnight in 4% paraformaldehyde at 4°C and embedded in paraffin. Paraffin sections (5 µm) were prepared. These sections were boiled in a microwave oven in 10 mM sodium citrate buffer (pH 6.0) for antigen retrieval and incubated with rabbit polyclonal anti-PLC1 antibody, followed by the procedure described in the technical bulletin of the tyramide signal amplification immunodetection kit (Perkin-Elmer, Boston, MA). Whole-mount CD31 staining of embryonal heads and yolk sacs was performed as described previously (36).

TUNEL assay and BrdU labeling. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assays were performed with an ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (CHEMICON) according to the manufacturer's recommendations. bromodeoxyuridine (BrdU) labeling was performed with a 5-Bromo-2'-Deoxyuridine Labeling and Detection Kit II (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's recommendations by intraperitoneal injection of BrdU into pregnant mice.

Electron microscopy. Placentas were fixed with 3% glutaraldehyde in 0.1 M phosphate buffer (pH 7.3). Specimens were postfixed with 2% osmium tetroxide for 2 h, block stained with 3% uranyl acetate for 2 h, and embedded in epoxy resin. Thin sections were cut, stained with uranyl acetate and lead citrate, and examined with a Hitachi H-800 transmission electron microscope.

Tetraploid chimera experiment. Two-cell-stage embryos were obtained from the oviducts of B6C3F1 females at embryonic day 1.5 (E1.5). The two-cell-stage embryos were placed in 0.3 M mannitol and aligned in a 5-V AC field and fused with two 40-µs 150-V DC pulses from a 1-mm electrode and a BTX Electro Cell Manipulator 2001 electrofusion apparatus (BTX, San Diego, CA). Fused embryos were cultured overnight. The zona was removed, and four- or eight-cell-stage diploid (2N) embryos derived from PLC1^–/– PLC3^+/– intercross matings were aggregated with four-cell-stage 4N B6C3F1 embryos. Chimeric embryos that developed successfully into blastocysts were transferred to the uterus of a pseudopregnant female.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Generation of PLC3 KO and PLC1/PLC3 DKO mice. To date, KO mice for many PLC isozymes have been generated and analyzed (5). Interestingly, these KO mice displayed distinct phenotypes, suggesting that although there are as many as 13 PLC isozymes, each has unique physiological functions. Therefore, we attempted to elucidate the physiological functions of PLC3 by generating and analyzing PLC3 KO mice. We first searched the Omni Bank embryonic stem (ES) cell library (Lexicon Genetics Incorporated) and identified one ES cell clone (OST101546) that had a retroviral gene trap insertion between exon 1, which contains the translation initiation codon, and exon 2 of the PLC3 mRNA. ES cell clone OST101546 was used to generate the PLC3 KO mice (Fig. 1A). Disruption of PLC3 was confirmed by PCR analysis of genomic DNA (Fig. 1B) and Western blot analysis of protein from the heart (Fig. 1C). PLC3 KO mice were viable, fertile, and apparently normal (Fig. 1D). Western blot analysis revealed that the tissue distribution of PLC3 overlaps that of PLC1 (Fig. 1E), which shares high homology with PLC3 (Fig. 1F), suggesting that the two genes may be functionally redundant. To investigate this possibility, we next generated PLC1/PLC3 DKO mice (Fig. 1G). PLC1^–/– PLC3^+/– and PLC1^+/– PLC3^–/– mice appeared normal; however, progressive hair loss, which is the characteristic phenotype of PLC1 KO mice, was observed in the PLC1^–/– PLC3^+/– mice. Intercrosses of PLC1^–/– PLC3^+/– mice produced no PLC1/PLC3 DKO pups, indicating that double disruption of PLC1 and PLC3 results in embryonic lethality.

View larger version (47K): [in this window] [in a new window]

FIG. 1. Generation of PLC3 KO and PLC1/PLC3 DKO mice. (A) Genetic map of the genomic structure of the PLC3 gene. Exons are indicated by numbered boxes. Introns are lettered (a through n), and their approximate lengths in kbp are given. The structure of the retroviral trap vector to disrupt the mouse PLC3 is also shown. LTR, long terminal repeat; SA, splice acceptor site; geo, galactosidase-neomycin resistance fusion gene; pA, polyadenylation consensus site; PGK, PGK promoter; puro, puromycin resistance cassette; SD, splice donor site. The gene trap is inserted into intron a of the PLC3 gene as indicated by an arrow. (B) PCR genotyping. Genomic DNAs were isolated from tails of wild-type (+/+), heterozygous (+/–), and PLC3 KO (–/–) mice. W, wild type; M, mutant. (C) Western blot analysis of expression of PLC3 in heart from wild-type (+/+) and PLC3 KO (–/–) mice. (D) Dorsal view of PLC3+/+ and PLC3–/– mice. (E) Western blot analysis of the tissue distribution of PLC1 and PLC3. Protein (40 µg) was subjected to SDS-polyacrylamide gel electrophoresis, and Western blot analysis was performed. (F) Amino acid homology between PLC1 and PLC3. Numbers indicate the percentage of similar amino acids. PH, pleckstrin homology domain; EF, EF-hand motif; X, X domain; Y, Y domain; C2, C2 domain. (G) Genotyping of embryos from PLC1+/– PLC3+/– intercrosses at E11.5. Lane 5, PLC1/PLC3 DKO embryos. W, wild type; M, mutant.

To determine the time of embryonic lethality, embryos at various stages of gestation were isolated. By E10.5, PLC1/PLC3 DKO embryos were detected at the expected Mendelian frequency (Table 1) and were indistinguishable from PLC1^–/– PLC3^+/+ littermates. However, by E11.5, 43% of PLC1/PLC3 DKO embryos were dead or abnormal, and the proportion of dead or abnormal embryos had increased to 56% by E12.5. By E13.5, all PLC1/PLC3 DKO embryos were dead or visibly abnormal. At E11.5, most living PLC1/PLC3 DKO embryos appeared normal (Fig. 2A and B), but the hearts of some PLC1/PLC3 DKO embryos had stopped beating. At E12.5, the body sizes of PLC1/PLC3 DKO embryos were smaller than those of PLC1^–/– PLC3^+/+ embryos, and hemorrhages in the cardiac and ventral body wall regions were visible in some PLC1/PLC3 DKO embryos (Fig. 2D). In addition, the yolk sacs of PLC1/PLC3 DKO mice appeared pale, with few vessels and blood cells (Fig. 2E and F). These observations indicate that PLC1 and PLC3 are required for normal embryonic development.

View this table: [in this window] [in a new window]

TABLE 1. Genotypes of offspring from PLC1–/– PLC3+/– x PLC1–/– PLC3+/– mating

View larger version (72K): [in this window] [in a new window]

FIG. 2. Macroscopic and vascular abnormalities of PLC1/PLC3 DKO embryos and extraembryonic tissues. (A to F) Macroscopic views of embryos and yolk sacs. Views of E11.5 PLC1–/– PLC3+/+ (A) and E11.5 PLC1/PLC3 DKO (B) embryos and E12.5 PLC1–/– PLC3+/+ (C) and E12.5 PLC1/PLC3 DKO (D) embryos. Yolk sacs of E12.5 PLC1–/– PLC3+/+ (E) and E12.5 PLC1/PLC3 DKO (F) embryos are also shown. At E12.5, PLC1/PLC3 DKO embryos exhibit hemorrhaging in the cardiac and ventral body wall regions (arrow in panel D). (G to J) Whole-mount CD31 staining of E12.5 heads and yolk sacs. Vessels of the head regions in PLC1–/– PLC3+/+ embryos were well remodeled (arrow in panel G), whereas in PLC1/PLC3 DKO embryos, the vasculature of the head region was irregularly shaped (arrow in panel H). Yolk sac vessels of PLC1–/– PLC3+/+ embryos were well remodeled with both large (arrows in panel I) and small (arrowheads in panel I) vessels, whereas those of PLC1/PLC3 DKO embryos contained mostly equal-diameter vessels (arrowheads in panel J).

Vascular defects in PLC1/PLC3 DKO embryos. The vascular system undergoes significant development during midgestation, which is the time when PLC1/PLC3 DKO embryos die. Therefore, we investigated the development of the vascular system in PLC1/PLC3 DKO embryos. Development of the embryonic vascular system involves two distinct processes: vasculogenesis and angiogenesis. During vasculogenesis, angioblasts are committed to an endothelial cell fate and form the primitive vascular plexus. The endothelial cells in the primitive vascular plexus then proliferate, migrate, and form complex vascular networks that contain vessels with various diameters and many branches in a process known as angiogenesis. In PLC1/PLC3 DKO embryos, vasculogenesis occurred normally (data not shown); however, some defects in angiogenesis were observed. At E12.5, vascular remodeling into small and large vessels had occurred in the head region of PLC1^–/– PLC3^+/+ embryos (Fig. 2G), whereas large-diameter vessels, which appeared to be irregularly shaped, were observed in the head region of PLC1/PLC3 DKO embryos (Fig. 2H). In addition, yolk sacs of E12.5 PLC1^–/– PLC3^+/+ embryos contained a complex vascular network that was composed of large- and small-diameter vessels (Fig. 2I), whereas yolk sacs from PLC1/PLC3 DKO embryos contained a relatively simple vascular network that consisted of equal-diameter vessels (Fig. 2J).

Thus, angiogenic remodeling did not occur normally in PLC1/PLC3 DKO embryos. However, these vascular defects were observed only in embryos that were obviously abnormal or already dead. Therefore, we speculated that there was another defect that contributed to embryonic lethality in PLC1/PLC3 DKO embryos.

Abundant expression of PLC1 and PLC3 in placenta. Around E11.5 to E13.5, placental defects are one of the main causes of embryonic lethality. Therefore, we examined expression of PLC1 and PLC3 in various tissues, including the placenta. Western blotting of tissues from E11.5 embryos revealed that both PLC1 and PLC3 exist most abundantly in the placenta (Fig. 3A). We confirmed that PLC1 levels were comparable between maternal decidual tissue and the embryonic origin of the placenta, whereas PLC3 was expressed more abundantly in the maternal part, but a significant level of PLC3 protein was still detected in the embryonic part (Fig. 3B). The embryonic portion of the placenta is composed mainly of trophoblasts. Therefore, we examined the expression of PLC1 and PLC3 in trophoblast stem (TS) cells, which differentiate into giant trophoblasts by depleting culture medium of fibroblast growth factor (30). PLC1 and PLC3 levels in lysates of TS cells were significantly higher than those of mouse embryonic fibroblasts, although the levels of PLC1 and PLC3 did not change during differentiation of TS cells (Fig. 3C). Furthermore, we carried out immunohistochemical analysis. Immunohistochemical analysis with anti-PLC1 antibody showed that PLC1 was expressed abundantly in trophoblasts of wild-type placentas (Fig. 3D and F), although PLC3 expression could not be detected because of the unavailability of our anti-PLC3 antibody for immunohistochemical analysis (data not shown). We also confirmed that PLC1 immunoreactivity was not detected in placentas of PLC1 KO mice (Fig. 3E), indicating that the signal is specific. These data indicate that PLC1 and PLC3 are expressed at high levels in trophoblasts of the placenta.

View larger version (73K): [in this window] [in a new window]

FIG. 3. Expression of PLC1 and PLC3 in placenta and trophoblast. (A) Western blot analysis of expression of PLC1 and PLC3 in embryonic and extraembryonic tissues at E11.5. (B) Western blot analysis of expression of PLC1 and PLC3 in fetal and maternal parts of the placenta. (C) PLC1 and PLC3 are expressed at high levels in TS cells. MEF, mouse embryonic fibroblast; Stem, undifferentiated TS cells; Day 2, Day 4, and Day 6, TS cells were induced to differentiate for 2 days, 4 days, and 6 days, respectively. ß-Actin (A to C) was included as a loading control. (D to F) Immunohistochemical detection of PLC1 in the placenta. Immunohistochemical staining of wild-type (D and F) and PLC1 KO (E) placentas at E11.5 with a polyclonal anti-PLC1 antibody. (F) Magnified view of panel D. Bars: D and E (shown in panel D) = 100 µm; F= 50 µm.

Reduced vascularization of the labyrinth area in PLC1/PLC3 DKO placenta. Because PLC1 and PLC3 are expressed at high levels in the placenta, we analyzed morphological changes in placentas from PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO embryos by HE staining. The embryonic part of the placenta is composed of three distinct trophoblast cell layers, the labyrinth layer, the spongiotrophoblast layer, and the giant trophoblast layer, moving from the embryo side to the maternal side (28). The labyrinth layer contains a large number of maternal and embryonic vessels and is the site of oxygen, nutrient, and waste exchange between the mother and the embryo. At E10.5, the structures of the labyrinth layers in PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas were indistinguishable. The numbers of embryonic and maternal vessels were also similar (Fig. 4A to D). At this stage, embryonic vessels (Fig. 4C and D) in the labyrinth area could be discriminated from maternal vessels (Fig. 4C and D) on the basis of differences in hemocyte morphology. However, at E11.5, we observed a remarkable difference in the labyrinth structure between PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas. The labyrinth layer of PLC1^–/– PLC3 ^+/+ placentas contained many maternal and embryonic vessels (Fig. 4E and G), whereas the numbers of these vessels in the labyrinth layer of PLC1/PLC3 DKO placentas were severely reduced (Fig. 4F and H). We also noticed that the labyrinth layer of PLC1^–/– PLC3^+/+ placentas was reddish, whereas the color of PLC1/PLC3 DKO placentas was somewhat yellowish (data not shown), suggesting reduced vascularization. These abnormalities were already observed in apparently normal PLC1/PLC3 DKO embryos at E11.5. When we calculated the ratio of the vascularized area to the total labyrinth area using NIH Image software, the ratio in PLC1/PLC3 DKO placentas was much lower (0.15 ± 0.038) than that in PLC1^–/– PLC3^+/+ placentas (0.27 ± 0.035) (Fig. 4I). The ratios of the vascularized area to the total labyrinth area were comparable in PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas at E10.5, suggesting that the abnormal morphological changes in the PLC1/PLC3 DKO placenta occur between E10.5 and E11.5. These abnormalities lead to insufficient exchange of gas, nutrients, and waste and therefore are likely to cause the midgestational embryonic lethality of PLC1/PLC3 DKO mice.

View larger version (102K): [in this window] [in a new window]

FIG. 4. Histological abnormalities in placentas of PLC1/PLC3 DKO mice. (A to H) HE staining of placenta sections from PLC1–/– PLC3+/+ (A, C, E, and G) and PLC1/PLC3 DKO (B, D, F, and H) embryos at E10.5 (A to D) and E11.5 (E to H). The arrows indicate embryonal vessels, and the arrowheads indicate maternal vessels. la, labyrinth area. Note that vascularization is reduced in the labyrinth area of the PLC1/PLC3 DKO placenta (F and H). (I) For quantification, the ratio of the vascularized area to the total labyrinth area was calculated with NIH Image software. Values represent the average ratios in five fields from five sections from different mice. Statistical significance was determined by Student's t test; the error bars indicate standard deviations. Bars: E and F (shown in panel E) = 100 µm; G and H (shown in panel G) = 50 µm.

Reduced proliferation and aberrant apoptosis in cells of PLC1/PLC3 DKO labyrinth area. The developmental defect in the labyrinth area of PLC1/PLC3 DKO mice suggests that proliferation of cells in this area is abnormal. Therefore, we examined the proliferative activity of cells in the labyrinth layer using BrdU incorporation. At E11.5, the PLC1^–/– PLC3^+/+ labyrinth layer contained many BrdU-positive cells (Fig. 5A and C). In contrast, the PLC1/PLC3 DKO labyrinth area displayed low BrdU incorporation (Fig. 5B and D). We also found that the labyrinth layer of the PLC1/PLC3 DKO placenta contained necrotic or apoptotic cells (Fig. 5E). Therefore, we next analyzed apoptosis in sections of the placenta using the TUNEL technique. Few or no TUNEL-positive cells were observed in the labyrinth layer of PLC1^–/– PLC3^+/+ placentas (Fig. 5F), whereas many TUNEL-positive cells were present in the labyrinth layer of PLC1/PLC3 DKO placentas (Fig. 5G and H). The necrotic or apoptotic cells exhibited an elongated morphology and were similar to syncytiotrophoblasts, which are located between a layer of mononuclear trophoblasts that line the maternal sinusoids and fetal endothelial cells and play a critical role in nutrient transport (28). We then performed ultrastructural analysis of cells in the labyrinth layer of PLC1/PLC3 DKO mice to identify dead cells and confirm the presence of features associated with apoptosis. In the PLC1^–/– PLC3^+/+ placenta, we observed endothelial cells, syncytiotrophoblasts, and mononucleated trophoblasts, which have intact cellular structure, between the embryonic vessels and maternal vessels (Fig. 5I). In contrast, vacuolation of nuclei (Fig. 5J, K, L, and M) and trophoblast fragmentation (Fig. 5J, K, N, O, and P) were observed in the labyrinth area of PLC1/PLC3 DKO placentas. Such trophoblast fragmentation and nuclear vacuolation were never observed in PLC1^–/– PLC3^+/+ placentas (Fig. 5I). In addition, endothelial cells of PLC1/PLC3 DKO placentas appeared normal even when the surrounding trophoblasts had died (Fig. 5J, K, O, and P), indicating that apoptosis of PLC1/PLC3 DKO trophoblasts is a primary phenomenon. Furthermore, electron microscopy revealed that the dead cells were positioned mainly just outside of embryonic endothelial cells (Fig. 5J, K, O, and P), indicating that the dead cells in PLC1/PLC3 DKO placentas were syncytiotrophoblasts. These results were consistent with those of HE (Fig. 5E) and TUNEL staining (Fig. 5H) and suggest that PLC1 and PLC3 influence the survival and proliferation of trophoblasts in the labyrinth layer of the placenta.

View larger version (137K): [in this window] [in a new window]

FIG. 5. Apoptotic and proliferative defects in trophoblasts of PLC1/PLC3 DKO placenta. (A to D) Proliferative activity was determined by BrdU incorporation analysis of labyrinth layer cells in PLC1–/– PLC3+/+ (A and C) and PLC1/PLC3 DKO (B and D) placentas. (C and D) Higher magnifications of the fields in panels A and B, respectively. HE (E) and TUNEL staining (F to H) of PLC1–/– PLC3+/+ (F) and PLC1/PLC3 DKO (E, G, and H) placentas. Apoptotic or necrotic cells were observed in the labyrinth area of the PLC1/PLC3 DKO placenta (arrows in panel E). (H) Higher magnification of the field in panel G. TUNEL-positive cells were observed in the labyrinth area of the PLC1/PLC3 DKO placenta (arrows in panel H). (I to P) Ultrastructural analysis of cells in PLC1–/– PLC3+/+ (I) and DKO (J to P) labyrinth layers. Note that the structure composed of mononuclear trophoblast (Mono), syncytiotrophoblast (SynT), and endothelial cell (Endo) is intact in the PLC1–/– PLC3+/+ labyrinth (I). Arrows (J to M) indicate vacuolation of nuclei in apoptotic trophoblasts. Asterisks (J, K, N, O, and P) indicate fragmented trophoblasts. Arrowheads (J, K, O, and P) indicate endothelial cells. e, embryonic vessels; m, maternal vessels. Bars: A and B (shown in panel A) = 100 µm; C and D (shown in panel C) = 100 µm; E = 50 µm; F and G (shown in panel F) = 100 µm; H = 50 µm; I = 2 µm; J = 2 µm; K = 2 µm; L = 1 µm; M = 1 µm; N = 2 µm; O = 2 µm; P = 1 µm.

Rescue of PLC1/PLC3 DKO embryos from embryonic lethality by supplying wild-type placenta. Because PLC1/PLC3 DKO embryos show vascular defects (Fig. 2G to J), as well as placental trophoblast defects, we attempted to examine whether the primary cause of embryonic lethality of PLC1/PLC3 DKO mice is the placental trophoblast defect. We aggregated wild-type 4N embryos with 2N embryos derived from PLC1^–/– PLC3^+/– intercrosses. In this case, the wild-type 4N cells contributed exclusively to the placental trophoblast cells and endoderm of the yolk sac, whereas the 2N cells contributed mainly to the embryo proper (12) (Fig. 6A). Thus, if the embryonic lethality of PLC1/PLC3 DKO mice is due only to a placental trophoblast defect, PLC1/PLC3 DKO embryos with wild-type placentas should survive beyond E13.5, the time when all PLC1/PLC3 DKO embryos were dead or abnormal. With this method, we detected 2 living PLC1/PLC3 DKO embryos among 16 embryos at E14.5 (Fig. 6B to D). We also examined the morphology of the placentas of PLC1/PLC3 DKO mice rescued by tetraploid aggregation. In contrast to the labyrinth area of the PLC1/PLC3 DKO placenta (Fig. 4F and H), the placentas of rescued PLC1/PLC3 DKO embryos contained many maternal and embryonic vessels, although the ratio of the vascularized area to the total labyrinth area in rescued PLC1/PLC3 DKO placentas was slightly lower than that of control placentas (Fig. 6E to G). These results clearly indicate that the embryonic lethality observed in PLC1/PLC3 DKO mice is caused primarily and mainly by trophoblast defects.

View larger version (61K): [in this window] [in a new window]

FIG. 6. Rescue of PLC1/PLC3 DKO placenta and embryo by tetraploid aggregation method. (A) Strategy of tetraploid chimera generation. 4N wild-type cells (+/+) were generated by electrofusion of 2N wild-type cells, and then 4N wild-type cells and 2N cells from intercrosses between PLC1–/– PLC3+/– (DKO; 1–/– 3+/– and 1–/– 3+/+) were aggregated. Blastocysts resulting from the aggregations were transferred into the uteri of pseudopregnant recipient mice. (B) Number of embryos generated by 4N aggregation method at E14.5. Aggregation of 4N wild-type cells and 2N cells from PLC1–/– PLC3+/– intercrosses was carried out. (C and D) Macroscopic views of rescued PLC1–/– PLC3+/+ (C) and PLC1/PLC3 DKO (D) embryos at E14.5. No obvious abnormalities were observed in the rescued PLC1/PLC3 DKO embryos. (E and F) HE staining of sections of placentas from rescued PLC1–/– PLC3+/+ (E) and PLC1/PLC3 DKO (F) embryos at E14.5. (G) Quantification of the ratio of vascularized area to total labyrinth area in nonrescued or 4N aggregation-rescued placenta. The values represent the average ratios in four fields from two sections from different tetraploid rescued mice (4N) and in five fields from five sections from different nonrescued mice (non). Statistical significance was determined by Student's t test. n.s., not significant. The error bars represent standard deviations.

Top Abstract Introduction Materials and Methods Results Discussion References

 
In the present study, we attempted to elucidate the physiological functions of PLC3 by analyzing PLC3 KO mice (Fig. 1A to C). PLC3 KO mice appeared normal (Fig. 1D); however, we cannot rule out the possibility that functional abnormalities are present in some organs or systems of PLC3 KO mice. PLC3 has the highest sequence homology to PLC1, and the proteins have similar tissue distribution patterns (Fig. 1E and F). In addition, PLC1 KO mice showed no obvious abnormalities, except for disturbance of skin homeostasis and runting (18). These facts suggest that PLC1 and PLC3 are functionally redundant and that the phenotypes were masked in single-gene KO mice. Therefore, we generated PLC1/3 DKO mice and found that these mice died in midgestation (Table 1).

The primary cause of embryonic lethality was defective development of the placenta. The placenta is composed of the maternal decidual tissue and a fetal portion that consists of three distinct trophoblast cell layers. Among these layers, the labyrinth layer contains many maternal and fetal vessels and plays a critical role in the exchange of nutrients and gas between the mother and the embryo. Therefore, normal placental function is essential for development of the embryo. We found that the labyrinth layer of PLC1/PLC3 DKO placentas contains fewer maternal and embryonic vessels (Fig. 4F and H). In addition, trophoblasts of the labyrinth layer of PLC1/PLC3 DKO placentas displayed aberrant cell death (Fig. 5E, G, and H). Cell death of some endothelial cells was also observed. However, electron microscopy revealed that trophoblasts died earlier than endothelial cells (Fig. 5J, K, O, and P). Therefore, a trophoblast abnormality was the primary cause of aberrant cell death and reduced proliferation of cells (Fig. 5B and D) in the placental labyrinth area, and death of endothelial cells may be a secondary effect of the death of surrounding trophoblasts. Because trophoblasts secrete several angiogenic factors, which play important roles in the growth and survival of endothelial cells and trophoblasts (38), it is possible that PLC1/PLC3 DKO trophoblasts secret insufficient angiogenic factors, which leads to reduced vascularization in PLC1/PLC3 DKO placentas. Therefore, we examined the expression levels of angiogenic factors, such as vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), angiopoietin 1, and angiopoietin 2 in E11.5 PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas by reverse transcription-PCR analysis and found that there were no significant differences in the expression levels of these genes between PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas (data not shown). We also found that the labyrinth structures were normal and that many fetal and maternal vessels were present in PLC1/PLC3 DKO placentas at E10.5 (Fig. 4B and D). This suggests that chorioallantoic fusion and branching occurred normally and that the fetal and maternal vessels in the labyrinth area are formed at this stage. Therefore, PLC1 and PLC3 may not be essential for morphogenesis of the labyrinth area by E10.5 but may be required for the survival of trophoblasts and maintenance of normal labyrinth structure at later stages.

The labyrinth area contains several distinct subtypes of trophoblasts that are present in specific locations, and these cell types can be readily distinguished on the basis of their positions and morphologies (28, 32). HE staining, TUNEL staining, and electron microscopy revealed that placental defects in PLC1/PLC3 DKO mice were due mainly to a syncytiotrophoblast abnormality (Fig. 5E, H, K, and O). Syncytiotrophoblast formation is a unique process that involves cell cycle exit and then fusion of these cells to form a syncytium (28). However, very little is known about the mechanism that underlies fusion of mouse trophoblasts. We investigated the expression levels of syncytins, which was reported to play the critical role in syncytiotrophoblast formation (2, 16), in E11.5 PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas by reverse transcription-PCR analysis and found that there were no remarkable differences in the expression levels of syncytin between PLC1^–/– PLC3^+/+ and PLC1/PLC3 DKO placentas (data not shown). Syncytiotrophoblasts play critical roles in normal placental function and embryo development. Exchange of nutrients and waste in the labyrinth area is dependent on syncytiotrophoblast functions, including endocytosis, exocytosis, and transcytosis (4). Phosphoinositide metabolism has been reported to be involved in membrane fusion or trafficking events, such as clathrin-mediated internalization of receptors or exocytosis of neurotransmitters (11, 33). Therefore, phosphoinositide metabolism may play important roles in the formation and function of syncytiotrophoblasts, and disturbance of phosphoinositide metabolism by deletion of the PLC1 and PLC3 genes may lead to syncytiotrophoblast abnormalities.

Because some dead or abnormal PLC1/PLC3 DKO embryos show vascular defects (Fig. 2G to J) in addition to placental defects, we used the tetraploid aggregation technique (Fig. 6A) to clarify placental trophoblast defects. The embryonic lethality by E13.5 was rescued by this method (Fig. 6B to F), indicating clearly that trophoblast abnormalities cause lethality of PLC1/PLC3 DKO embryos at this stage. However, the defect in vascularization of the labyrinth area of rescued PLC1/PLC3 DKO mice was not completely rescued, although a drastic improvement in vascularization was observed (Fig. 6G). It has been reported that wild-type 4N cells contribute exclusively to placental trophoblasts and endoderm of the yolk sac, whereas PLC1/PLC3 DKO 2N cells contribute to the embryo proper. However, some populations of 2N cells contribute partially to placental trophoblasts, resulting in a placenta that is a chimera of 4N and 2N cells (12). Therefore, the labyrinth area of rescued PLC1/PLC3 DKO embryos may contain a few 2N PLC1/PLC3 DKO trophoblasts, and these PLC1/PLC3 DKO trophoblasts may inhibit complete rescue of vascularization in aggregation experiments.

To date, many genes, including those for transcription factors, growth factors/receptors, and other signal transduction molecules, have been reported to be involved in the development of the placental labyrinth layer (32). However, the molecules upstream and downstream in signaling pathways involving these genes are not fully understood. The results of the present study indicate that PLC1 and PLC3 must also be considered in placental development. Because PLC activation induces elevation of intracellular calcium levels and protein kinase C activation, leading to modulation of various downstream molecules, it will be very interesting to clarify how PLC1 and PLC3 affect placental development. One signal transduction pathway that is involved in placental morphogenesis is Rho signaling. It was recently reported that the deleted in liver cancer 1 (DLC-1) gene, a Rho GTPase-activating protein, and the rho-associated kinase 2 (ROCKII) gene are essential for placental labyrinth layer development (3, 31). Because DLC-1 binds directly to PLC1 to activate PLC1 enzyme activity (9, 26) and because RhoA inhibits PLC1 enzyme activity (8), Rho signaling may modulate PLC1 activity during placental development. Together, we show here for the first time that PLC1 and PLC3 are required for normal morphogenesis and function of the placenta in mice. Although the gross anatomy and physiology of the mouse and human placentas are different, they share considerable cellular and molecular characteristics (25). In addition, intrauterine growth retardation with labyrinth vascular defects has been observed in human preeclampsia and missed abortion (22). Therefore, it is very important to elucidate whether PLC1 and PLC3 play similar roles in the human placenta, and understanding the signaling pathways that involve PLC1 and PLC3 may clarify the events in the process of placentogenesis and contribute to the development of treatments for missed abortion and preeclampsia.

 
We thank Pann-Ghill Suh and Mizuho Sato for PLC1 antibodies and technical support, respectively.

This work was supported by a Grant-in-Aid for General Scientific Research from the Japan Ministry of Education, Science, Sports, and Culture and grants from The Naito Foundation and the Uehara Memorial Foundation.

 
* Corresponding author. Mailing address: Laboratory of Genome and Biosignal, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, 192-0392 Tokyo, Japan. Phone: 81-426-76-7214. Fax: 81-426-76-7249. E-mail: kfukami{at}ls.toyaku.ac.jp.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Berridge, M. J., and R. F. Irvine. 1984. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 312:315-321.[CrossRef][Medline]
2
2. Dupressoir, A., G. Marceau, C. Vernochet, L. Benit, C. Kanellopoulos, V. Sapin, and T. Heidmann. 2005. Syncytin-A and syncytin-B, two fusogenic placenta-specific murine envelope genes of retroviral origin conserved in Muridae. Proc. Natl. Acad. Sci. USA 102:725-730.[Abstract/Free Full Text]
3
3. Durkin, M. E., M. R. Avner, C. G. Huh, B. Z. Yuan, S. S. Thorgeirsson, and N. C. Popescu. 2005. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett. 579:1191-1196.[CrossRef][Medline]
4
4. Fuchs, R., and I. Ellinger. 2004. Endocytic and transcytotic processes in villous syncytiotrophoblast: role in nutrient transport to the human fetus. Traffic 5:725-738.[CrossRef][Medline]
5
5. Fukami, K. 2002. Structure, regulation, and function of phospholipase C isozymes. J. Biochem. (Tokyo) 131:293-299.[Free Full Text]
6
6. Fukami, K., K. Nakao, T. Inoue, Y. Kataoka, M. Kurokawa, R. A. Fissore, K. Nakamura, M. Katsuki, K. Mikoshiba, N. Yoshida, and T. Takenawa. 2001. Requirement of phospholipase C4 for the zona pellucida-induced acrosome reaction. Science 292:920-923.[Abstract/Free Full Text]
7
7. Fukami, K., M. Yoshida, T. Inoue, M. Kurokawa, R. A. Fissore, N. Yoshida, K. Mikoshiba, and T. Takenawa. 2003. Phospholipase C4 is required for Ca2+ mobilization essential for acrosome reaction in sperm. J. Cell Biol. 161:79-88.[Abstract/Free Full Text]
8
8. Hodson, E. A., C. C. Ashley, A. D. Hughes, and J. S. Lymn. 1998. Regulation of phospholipase C-delta by GTP-binding proteins-rhoA as an inhibitory modulator. Biochim. Biophys. Acta 1403:97-101.[Medline]
9
9. Homma, Y., and Y. Emori. 1995. A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J. 14:286-291.[Medline]
10
10. Irino, Y., H. Cho, Y. Nakamura, M. Nakahara, M. Furutani, P. G. Suh, T. Takenawa, and K. Fukami. 2004. Phospholipase C -type consists of three isozymes: bovine PLC2 is a homologue of human/mouse PLC4. Biochem. Biophys. Res. Commun. 320:537-543.[CrossRef][Medline]
11
11. Itoh, T., and T. Takenawa. 2004. Regulation of endocytosis by phosphatidylinositol 4,5-bisphosphate and ENTH proteins. Curr. Top. Microbiol. Immunol. 282:31-47.[Medline]
12
12. James, R. M., A. H. Klerkx, M. Keighren, J. H. Flockhart, and J. D. West. 1995. Restricted distribution of tetraploid cells in mouse tetraploiddiploid chimaeras. Dev. Biol. 167:213-226.[CrossRef][Medline]
13
13. Katan, M. 1998. Families of phosphoinositide-specific phospholipase C: structure and function. Biochim. Biophys. Acta 1436:5-17.[Medline]
14
14. Kato, H., K. Fukami, F. Shibasaki, Y. Homma, and T. Takenawa. 1992. Enhancement of phospholipase C delta 1 activity in the aortas of spontaneously hypertensive rats. J. Biol. Chem. 267:6483-6487.[Abstract/Free Full Text]
15
15. Kelley, G. G., S. E. Reks, J. M. Ondrako, and A. V. Smrcka. 2001. Phospholipase C: a novel Ras effector. EMBO J. 20:743-754.[CrossRef][Medline]
16
16. Mi, S., X. Lee, X. Li, G. M. Veldman, H. Finnerty, L. Racie, E. LaVallie, X. Y. Tang, P. Edouard, S. Howes, J. C. Keith, Jr., and J. M. McCoy. 2000. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 403:785-789.[CrossRef][Medline]
17
17. Nakahara, M., M. Shimozawa, Y. Nakamura, Y. Irino, M. Morita, Y. Kudo, and K. Fukami. 2005. A novel phospholipase C, PLC2, is a neuron-specific isozyme. J. Biol. Chem. 280:29128-29134.[Abstract/Free Full Text]
18
18. Nakamura, Y., K. Fukami, H. Yu, K. Takenaka, Y. Kataoka, Y. Shirakata, S. Nishikawa, K. Hashimoto, N. Yoshida, and T. Takenawa. 2003. Phospholipase C1 is required for skin stem cell lineage commitment. EMBO J. 22:2981-2991.[CrossRef][Medline]
19
19. Nishizuka, Y. 1988. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334:661-665.[CrossRef][Medline]
20
20. Ochocka, A. M., and T. Pawelczyk. 2003. Isozymes delta of phosphoinositide-specific phospholipase C and their role in signal transduction in the cell. Acta Biochim. Pol. 50:1097-1110.[Medline]
21
21. Rebecchi, M. J., and S. N. Pentyala. 2000. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol. Rev. 80:1291-1335.[Abstract/Free Full Text]
22
22. Regnault, T. R., H. L. Galan, T. A. Parker, and R. V. Anthony. 2002. Placental development in normal and compromised pregnancies—a review. Placenta 23(Suppl. A):S119-S129.[Medline]
23
23. Rhee, S. G. 2001. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 70:281-312.[CrossRef][Medline]
24
24. Rhee, S. G., and Y. S. Bae. 1997. Regulation of phosphoinositide-specific phospholipase C isozymes. J. Biol. Chem. 272:15045-15048.[Free Full Text]
25
25. Rossant, J., and J. C. Cross. 2001. Placental development: lessons from mouse mutants. Nat. Rev. Genet. 2:538-548.[Medline]
26
26. Sekimata, M., Y. Kabuyama, Y. Emori, and Y. Homma. 1999. Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J. Biol. Chem. 274:17757-17762.[Abstract/Free Full Text]
27
27. Shimohama, S., Y. Homma, T. Suenaga, S. Fujimoto, T. Taniguchi, W. Araki, Y. Yamaoka, T. Takenawa, and J. Kimura. 1991. Aberrant accumulation of phospholipase C-delta in Alzheimer brains. Am. J. Pathol. 139:737-742.[Abstract]
28
28. Simmons, D. G., and J. C. Cross. 2005. Determinants of trophoblast lineage and cell subtype specification in the mouse placenta. Dev. Biol. 284:12-24.[CrossRef][Medline]
29
29. Song, C., C. D. Hu, M. Masago, K. Kariyai, Y. Yamawaki-Kataoka, M. Shibatohge, D. Wu, T. Satoh, and T. Kataoka. 2001. Regulation of a novel human phospholipase C, PLC, through membrane targeting by Ras. J. Biol. Chem. 276:2752-2757.[Abstract/Free Full Text]
30
30. Tanaka, S., T. Kunath, A. K. Hadjantonakis, A. Nagy, and J. Rossant. 1998. Promotion of trophoblast stem cell proliferation by FGF4. Science 282:2072-2075.[Abstract/Free Full Text]
31
31. Thumkeo, D., J. Keel, T. Ishizaki, M. Hirose, K. Nonomura, H. Oshima, M. Oshima, M. M. Taketo, and S. Narumiya. 2003. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23:5043-5055.[Abstract/Free Full Text]
32
32. Watson, E. D., and J. C. Cross. 2005. Development of structures and transport functions in the mouse placenta. Physiology (Bethesda) 20:180-193.[CrossRef][Medline]
33
33. Wenk, M. R., and P. De Camilli. 2004. Protein-lipid interactions and phosphoinositide metabolism in membrane traffic: insights from vesicle recycling in nerve terminals. Proc. Natl. Acad. Sci. USA 101:8262-8269.[Abstract/Free Full Text]
34
34. Williams, R. L. 1999. Mammalian phosphoinositide-specific phospholipase C. Biochim. Biophys. Acta 1441:255-267.[Medline]
35
35. Yagisawa, H., Y. Emori, and H. Nojima. 1991. Phospholipase C genes display restriction fragment length polymorphisms between the genomes of normotensive and hypertensive rats. J. Hypertens. 9:303-307.[CrossRef][Medline]
36
36. Yamazaki, D., S. Suetsugu, H. Miki, Y. Kataoka, S. Nishikawa, T. Fujiwara, N. Yoshida, and T. Takenawa. 2003. WAVE2 is required for directed cell migration and cardiovascular development. Nature 424:452-456.[CrossRef][Medline]
37
37. Zambrowicz, B. P., G. A. Friedrich, E. C. Buxton, S. L. Lilleberg, C. Person, and A. T. Sands. 1998. Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392:608-611.[CrossRef][Medline]
38
38. Zhou, Y., V. Bellingard, K. T. Feng, M. McMaster, and S. J. Fisher. 2003. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C. Dev. Biol. 263:114-125.[CrossRef][Medline]

---

Molecular and Cellular Biology, December 2005, p. 10979-10988, Vol. 25, No. 24
0270-7306/05/$08.00+0     doi:10.1128/MCB.25.24.10979-10988.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Dupressoir, A., Vernochet, C., Bawa, O., Harper, F., Pierron, G., Opolon, P., Heidmann, T. (2009). From the Cover: Syncytin-A knockout mice demonstrate the critical role in placentation of a fusogenic, endogenous retrovirus-derived, envelope gene. Proc. Natl. Acad. Sci. USA 106: 12127-12132 [Abstract] [Full Text]  
• Stallings, J. D., Zeng, Y. X., Narvaez, F., Rebecchi, M. J. (2008). Phospholipase C-{delta}1 Expression Is Linked to Proliferation, DNA Synthesis, and Cyclin E Levels. J. Biol. Chem. 283: 13992-14001 [Abstract] [Full Text]  
• Nakamura, Y., Ichinohe, M., Hirata, M., Matsuura, H., Fujiwara, T., Igarashi, T., Nakahara, M., Yamaguchi, H., Yasugi, S., Takenawa, T., Fukami, K. (2008). Phospholipase C-{delta}1 is an essential molecule downstream of Foxn1, the gene responsible for the nude mutation, in normal hair development. FASEB J. 22: 841-849 [Abstract] [Full Text]  
• Naito, Y., Okada, M., Yagisawa, H. (2006). Phospholipase C Isoforms Are Localized at the Cleavage Furrow during Cytokinesis. J Biochem 140: 785-791 [Abstract] [Full Text]  
• Takeda, K., Ho, V. C., Takeda, H., Duan, L.-J., Nagy, A., Fong, G.-H. (2006). Placental but Not Heart Defects Are Associated with Elevated Hypoxia-Inducible Factor {alpha} Levels in Mice Lacking Prolyl Hydroxylase Domain Protein 2. Mol. Cell. Biol. 26: 8336-8346 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, Y. Articles by Fukami, K. Search for Related Content PubMed PubMed Citation Articles by Nakamura, Y. Articles by Fukami, K.